Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOY7W3)

Drug Name
Artemisinin Drug Info
Synonyms
Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
Cross-matching ID
PubChem CID
68827
ChEBI ID
CHEMBL269671
CAS Number
CAS 63968-64-9
TTD Drug ID
D0S3WH
VARIDT Drug ID
DR01207
INTEDE Drug ID
DR0141

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cysteine and methionine metabolism 1.70 3.26e-1 43/50 (86%) ENOPH1;CDO1;SMS;...
Fatty acid degradation 1.69 1.94e-1 40/43 (93.02%) ACSL1;ADH1B;ACAA2;...
Mineral absorption 1.58 3.91e-1 48/60 (80%) MT1X;MT1F;MT1H;...
Melanoma 1.54 3.96e-1 68/72 (94.44%) PDGFRA;TP53;MET;...
Taurine and hypotaurine metabolism 1.50 4.79e-1 8/11 (72.73%) CDO1;GGT1;BAAT;...
Notch signaling pathway 1.50 4.05e-1 49/59 (83.05%) HEY1;NOTCH2;CTBP1;...
MAPK signaling pathway 1.49 3.61e-1 272/294 (92.52%) PDGFRA;TP53;NTRK2;...
Maturity onset diabetes of the young 1.48 3.68e-1 21/26 (80.77%) HHEX;NEUROD1;NR5A2;...
TGF-beta signaling pathway 1.44 4.26e-1 81/94 (86.17%) ID2;ID3;INHBB;...
Neurotrophin signaling pathway 1.43 4.41e-1 107/119 (89.92%) TP53;NTRK2;SOS2;...
Fatty acid elongation 1.43 4.04e-1 19/27 (70.37%) ACAA2;ELOVL5;HADH;...
Ras signaling pathway 1.41 4.15e-1 201/232 (86.64%) PDGFRA;NTRK2;PLAAT3;...
MicroRNAs in cancer 1.40 4.48e-1 146/310 (47.1%) PDGFRA;SLC7A1;TP53;...
Acute myeloid leukemia 1.38 4.66e-1 66/67 (98.51%) STAT5B;SOS2;MYC;...
Phosphonate and phosphinate metabolism 1.33 5.94e-1 5/6 (83.33%) CHPT1
Tryptophan metabolism 1.33 5.75e-1 35/42 (83.33%) KYAT3;ACAT1;AOC1;...
Valine, leucine and isoleucine degradation 1.32 5.73e-1 42/48 (87.5%) ACAA2;ACAT1;MCCC1;...
Tyrosine metabolism 1.32 5.43e-1 30/36 (83.33%) ADH1B;TYRP1;HGD;...
Circadian rhythm 1.32 5.24e-1 26/31 (83.87%) PER1;RORA;SKP1;...
Nicotinate and nicotinamide metabolism 1.31 5.11e-1 25/35 (71.43%) NNMT;NAMPT;CD38;...
Drug metabolism 1.30 5.21e-1 78/151 (51.66%) ADH1B;FMO2;GSTM3;...
Chronic myeloid leukemia 1.28 5.78e-1 72/76 (94.74%) TP53;STAT5B;SOS2;...
Ubiquitin mediated proteolysis 1.28 5.84e-1 87/140 (62.14%) STUB1;RHOBTB1;ELOC;...
JAK-STAT signaling pathway 1.25 6.68e-1 146/162 (90.12%) PDGFRA;STAT5B;SOS2;...
Cortisol synthesis and secretion 1.23 7.08e-1 58/65 (89.23%) PLCB1;PLCB4;GNAS;...
Tight junction 1.22 7.13e-1 130/169 (76.92%) AMOTL2;JAM2;MYL12B;...
Hippo signaling pathway 1.22 7.01e-1 120/186 (64.52%) ID2;FZD6;MYC;...
Inflammatory bowel disease 1.20 7.12e-1 58/65 (89.23%) TLR4;RORA;IFNG;...
Ether lipid metabolism 1.19 6.98e-1 32/49 (65.31%) CHPT1;PLAAT3;PLPP3;...
Pathogenic Escherichia coli infection 1.15 7.14e-1 152/197 (77.16%) TLR4;NFKBIB;ARPC4;...
Focal adhesion -1.33 3.71e-1 180/201 (89.55%) ROCK2;CCND1;COL4A2;...
Vibrio cholerae infection -1.33 3.71e-1 44/50 (88%) ATP6V0A1;ATP6V1E1;SEC61B;...
Natural killer cell mediated cytotoxicity -1.36 3.51e-1 99/131 (75.57%) SOS1;RAF1;TNFSF10;...
Viral myocarditis -1.40 2.81e-1 53/60 (88.33%) PRF1;EIF4G2;HLA-F;...
Epstein-Barr virus infection -1.41 2.74e-1 189/202 (93.56%) IRF9;FADD;BAK1;...
Sulfur metabolism -1.41 2.76e-1 9/10 (90%) SQOR;SELENBP1
N-Glycan biosynthesis -1.43 2.54e-1 38/50 (76%) DPM1;STT3A;ALG6;...
Axon guidance -1.43 2.64e-1 151/182 (82.97%) CDK5;BMP7;EPHA4;...
Fructose and mannose metabolism -1.43 2.65e-1 30/33 (90.91%) PFKFB4;PMM1;FBP2;...
Oxytocin signaling pathway -1.43 2.74e-1 128/154 (83.12%) PPP3R1;PPP1CA;ADCY2;...
Steroid hormone biosynthesis -1.45 2.59e-1 43/61 (70.49%) HSD17B7;SRD5A1;DHRS11;...
Caffeine metabolism -1.45 2.60e-1 5/6 (83.33%) NAT2;CYP2A6;NAT1
Glycosaminoglycan biosynthesis -1.46 2.70e-1 40/58 (68.97%) DSE;HS6ST1;EXT2;...
IL-17 signaling pathway -1.47 2.62e-1 84/94 (89.36%) FOS;MMP1;TRAF6;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.47 2.69e-1 20/26 (76.92%) PIGL;PIGO;PIGC;...
Amoebiasis -1.47 2.80e-1 99/102 (97.06%) RAB5C;ACTN1;LAMA4;...
Parkinson disease -1.49 2.69e-1 176/249 (70.68%) UBA1;PSMA7;PLCG1;...
Amino sugar and nucleotide sugar metabolism -1.51 2.36e-1 38/48 (79.17%) MPI;GFPT2;HK2;...
Salivary secretion -1.52 2.35e-1 76/93 (81.72%) ADCY2;ADRB2;CST2;...
Protein digestion and absorption -1.54 2.05e-1 78/103 (75.73%) COL11A2;COL6A1;COL7A1;...
VEGF signaling pathway -1.56 2.01e-1 50/59 (84.75%) RAF1;PIK3CA;AKT2;...
Protein processing in endoplasmic reticulum -1.57 1.95e-1 127/171 (74.27%) STT3A;HSPA8;CUL1;...
Prion disease -1.57 2.17e-1 209/273 (76.56%) PSMB1;C5;COX6A2;...
Diabetic cardiomyopathy -1.62 1.53e-1 162/203 (79.8%) MAPK10;TGFBR1;PIK3R1;...
Antigen processing and presentation -1.68 1.02e-1 60/78 (76.92%) TAP2;HLA-E;IFI30;...
Nitrogen metabolism -1.70 9.26e-2 16/17 (94.12%) CA9;CA12;CA2;...
Steroid biosynthesis -1.70 1.09e-1 19/20 (95%) SOAT1;FDFT1;EBP;...
Other types of O-glycan biosynthesis -1.70 1.36e-1 29/47 (61.7%) RFNG;POGLUT1;C1GALT1;...
Mucin type O-glycan biosynthesis -1.71 1.70e-1 20/36 (55.56%) GCNT1;C1GALT1;ST6GALNAC4;...
Proteasome -1.72 2.33e-1 44/46 (95.65%) PSMA7;PSMB1;PSMC2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H